Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CHINOOK THERAPEUTICS, INC.

(KDNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Chinook Therapeutics : Promotes Tom Frohlich to Operating Chief, Andrew King to Chief Scientific Officer

06/09/2021 | 09:17am EDT


© MT Newswires 2021
All news about CHINOOK THERAPEUTICS, INC.
07/12Chinook Therapeutics to Present at the William Blair Biotech Focus Conference..
GL
07/07Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq L..
GL
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell 2000 Growth Ind..
CI
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell 3000 Growth Ind..
CI
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell 2500 Growth Ind..
CI
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell Microcap Growth..
CI
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell 3000E Growth In..
CI
06/25CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) dropped from Russell Small Cap Comp ..
CI
06/21CHINOOK THERAPEUTICS, INC.(NASDAQGS : KDNY) added to S&P Biotechnology Select In..
CI
06/18CHINOOK : Q1 Earnings Snapshot
AQ
More news
Financials (USD)
Sales 2021 0,54 M - -
Net income 2021 -140 M - -
Net cash 2021 115 M - -
P/E ratio 2021 -4,09x
Yield 2021 -
Capitalization 581 M 581 M -
EV / Sales 2021 857x
EV / Sales 2022 2 467x
Nbr of Employees -
Free-Float 89,6%
Chart CHINOOK THERAPEUTICS, INC.
Duration : Period :
Chinook Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINOOK THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 13,03 $
Average target price 32,71 $
Spread / Average Target 151%
EPS Revisions
Managers and Directors
Eric L. Dobmeier Chairman, President & Chief Executive Officer
Eric Hands Claude Bjerkholt Chief Financial Officer
Alan Glicklich Chief Medical Officer
Andrew King Chief Scientific Officer
Tom Frohlich Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
CHINOOK THERAPEUTICS, INC.-17.84%581
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%68 112
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 232